A systemic review and meta-analysis on the impact of perioperative antiplatelets and anticoagulants on the clinical course of chronic subdural hematoma by Elmahdi, Ashraf
Royal College of Surgeons in Ireland
e-publications@RCSI
Masters theses/dissertations - taught courses Theses and Dissertations
11-15-2012
A systemic review and meta-analysis on the impact
of perioperative antiplatelets and anticoagulants on
the clinical course of chronic subdural hematoma
Ashraf Elmahdi
Royal College of Surgeons in Ireland, ashrafmahadi@yahoo.com
This Thesis is brought to you for free and open access by the Theses and
Dissertations at e-publications@RCSI. It has been accepted for inclusion in
Masters theses/dissertations - taught courses by an authorized
administrator of e-publications@RCSI. For more information, please
contact epubs@rcsi.ie.
Citation
Elmahdi A. A systemic review and meta-analysis on the impact of perioperative antiplatelets and anticoagulants on the clinical course
of chronic subdural hematoma. [MSc Thesis]. Dublin: Royal College of Surgeons in Ireland; 2012.
— Use Licence —
Creative Commons Licence:
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.
This thesis is available at e-publications@RCSI: http://epubs.rcsi.ie/mscttheses/17
 
 
The contents of the enclosed manuscript are confidential and should not be disclosed, or disseminated in any way, to any third party other than 
to staff or students of the Royal College of Surgeons in Ireland or an external examiner appointed for the purpose of reviewing the manuscript. 
A systemic review and meta-analysis on the impact 
of perioperative antiplatelets and anticoagulants on 
the clinical course of chronic subdural hematoma 
Ashraf Eltayeb Zein Elabdin Elmahdi 
Royal College of Surgeons in Ireland 
123 St Stephens Green, Dublin 2 
Ireland 
The Royal College of Surgeons of Edinburgh  
Nicolson Street Edinburgh EH8 9DW 
United Kingdom 
MRCSI, MRCSED 
Royal College of Surgeons in Ireland, 
National Surgical Training Centre 
Master of Surgery by Module 
Master of Surgery, MCh 
29/06/2012 
Neurosurgery Department 
Prof Ronan Conroy 
Prof Ciaran Bolger 
Word Count: 9849 excluding the references & appendices 
1 
 
  
The contents of the enclosed manuscript are confidential and should not be disclosed, or disseminated in any way, to any third party other than 
to staff or students of the Royal College of Surgeons in Ireland or an external examiner appointed for the purpose of reviewing the manuscript. 
2 
 
Candidate thesis declaration 
The candidate thesis declaration below should be inserted as a separate page after the title page 
in all copies of the thesis including the soft bound copies that are submitted for examination and 
the hard bound copy.  
I declare that this thesis, which I submit to RCSI for examination in consideration of the award 
of a higher degree Master of Surgery, MCh is my own personal effort. Where any of the content 
presented is the result of input or data from a related collaborative research programme this is 
duly acknowledged in the text such that it is possible to ascertain how much of the work is my 
own. I have not already obtained a degree in RCSI or elsewhere on the basis of this work. 
Furthermore, I took reasonable care to ensure that the work is original, and, to the best of my 
knowledge, does not breach copyright law, and has not been taken from other sources except 
where such work has been cited and acknowledged within the text.  
Signed ……………………………………………………………………. 
RCSI Student Number ……………………………………………………. 
Date………………………………………………………………………… 
 
 
 
 
 
The contents of the enclosed manuscript are confidential and should not be disclosed, or disseminated in any way, to any third party other than 
to staff or students of the Royal College of Surgeons in Ireland or an external examiner appointed for the purpose of reviewing the manuscript. 
Table of content 
Candidate thesis declaration ....................................................................................................... 2 
Table of content .......................................................................................................................... 3 
List of Figures ............................................................................................................................ 5 
List of Tables .............................................................................................................................. 5 
Abstract: ..................................................................................................................................... 6 
1.  Introduction .................................................................................................................... 9 
1.1  Background ............................................................................................................. 9 
1.2  Burden of the problem ........................................................................................... 11 
1.3  Anticoagulation ..................................................................................................... 13 
1.4  Why it is important to do this review: ................................................................... 15 
1.5  Aims and objectives .............................................................................................. 16 
2.  Materials & Methods .................................................................................................... 18 
2.1  Research protocol .................................................................................................. 18 
2.2  Search methods for identification of studies ......................................................... 19 
2.3  Selection of studies ................................................................................................ 19 
2.4  Data Extraction and management .......................................................................... 20 
2.5  Types of studies ..................................................................................................... 21 
2.6  Types of participants ............................................................................................. 21 
2.6.1  Inclusion criteria ............................................................................................. 21 
2.6.2  Exclusion criteria ............................................................................................ 21 
2.6.3  Population ....................................................................................................... 21 
2.6.4  Intervention ..................................................................................................... 21 
2.6.5  Control ............................................................................................................ 21 
2.7  Types of outcome measures .................................................................................. 22 
2.7.1  Primary outcomes ........................................................................................... 22 
2.7.2  Secondary outcomes ....................................................................................... 22 
2.8  Potential confounders ............................................................................................ 22 
2.9  Data collection ....................................................................................................... 22 
2.10  Data collection procedure ...................................................................................... 22 
2.11  Data protection ...................................................................................................... 22 
3 
 
  
The contents of the enclosed manuscript are confidential and should not be disclosed, or disseminated in any way, to any third party other than 
to staff or students of the Royal College of Surgeons in Ireland or an external examiner appointed for the purpose of reviewing the manuscript. 
2.12  Assessment of risk of bias ..................................................................................... 23 
2.13  Assessment of heterogeneity ................................................................................. 23 
2.14  Statistical analysis ................................................................................................. 24 
3.  Results .......................................................................................................................... 24 
3.1  Study Identification ............................................................................................... 24 
3.2  Study characteristics .............................................................................................. 25 
3.3  Risk of Bias ........................................................................................................... 32 
3.4  Effects of intervention ........................................................................................... 32 
3.4.1  Recurrent Subdural Hematoma ...................................................................... 32 
3.4.2  Bilateral subdural hematoma .......................................................................... 32 
3.4.3  Unknown indication of anticoagulation ......................................................... 33 
3.4.4  Time period to operation and reoperation ...................................................... 33 
3.4.5  Mortality ......................................................................................................... 34 
4.  Discussion .................................................................................................................... 37 
4.1  Statement of principle findings ............................................................................. 37 
4.2  Context of previous studies ................................................................................... 37 
4.3  Strengths and weaknesses ..................................................................................... 39 
4.4  Clinical implications .............................................................................................. 41 
5.  Conclusions .................................................................................................................. 47 
5.1  Implications for practice ........................................................................................ 47 
5.2  Implications for research ....................................................................................... 47 
References ................................................................................................................................ 49 
Appendix 1. PRISMA 2009 checklist ...................................................................................... 57 
Appendix 2. PRISMA 2009 flow diagram ............................................................................... 58 
Appendix 3. Search keywords .................................................................................................. 59 
Appendix 4. Data collection sheet ............................................................................................ 61 
Appendix 5. Modified table of bias .......................................................................................... 62 
Appendix 6. Draft paper for publication .................................................................................. 63 
 
 
4 
 
 
 
The contents of the enclosed manuscript are confidential and should not be disclosed, or disseminated in any way, to any third party other than 
to staff or students of the Royal College of Surgeons in Ireland or an external examiner appointed for the purpose of reviewing the manuscript. 
5 
 
List of Figures 
Figure 1. PRISMA flow diagram of search strategy. ............................................................... 26 
Figure 2. Meta-analysis of the antiplatelets/anticoagulant related recurrent chronic subdural 
hematoma ................................................................................................................................. 35 
Figure 3. Meta-analysis of the anticoagulants related bilateral chronic subdural hematoma .. 36 
 
 
List of Tables 
Table 1. Included studies of the recurrent subdural hematoma ................................................ 27 
Table 2. Included studies of bilateral subdural hematoma ....................................................... 28 
Table 3. Summary of the data of recurrence on anticoagulant ................................................. 29 
Table 4. Summary of the data of recurrence on antiplatelet ..................................................... 30 
Table 5. Summary of the data of bilateral chronic subdural hematoma ................................... 31 
Table 6. Unknown indication of anticoagulation ..................................................................... 33 
Table 7. Time period to operation/reoperation of participants ................................................. 34 
Table 8. Mortality rate of recurrent chronic subdural hematoma ............................................. 34 
Table 9. Mortality rate of bilateral chronic subdural hematoma .............................................. 34 
 
 
 
 
  
The contents of the enclosed manuscript are confidential and should not be disclosed, or disseminated in any way, to any third party other than 
to staff or students of the Royal College of Surgeons in Ireland or an external examiner appointed for the purpose of reviewing the manuscript. 
 
Abstract: 
Background: Chronic subdural hematoma is one of the most common conditions related to 
neurosurgical practice in the elderly. Reports about recurrence of patients on antiplatelets 
and/or anticoagulants are highly contradictory. Little current data exists regarding the outcome 
of chronic subdural hematoma patients on peri-operative medication related coagulopathy. 
We aimed to review the literature for studies about these drugs and outcome in chronic sub-
dural hematoma patients. 
Objectives: to perform a systematic review and meta-analysis of studies that examines the 
impact of antiplatelets and anticoagulants on the clinical evolution of chronic subdural hema-
toma. 
Methods: We searched the Cochrane Library, PubMed, Scirus, MEDLINE, EMBASE, and the 
American Association of Neurological Surgeons (AANS) Database, and the conference pro-
ceedings of the European Association of Neurosurgical Societies (EANS). We also checked the 
reference lists of all retrieved studies and Controlled Trials metaRegister to identify any fur-
ther studies. We searched the Internet using Google Scholar. We also contacted experts in the 
field as well as authors of the included studies. Searching was not restricted by date, language 
or publication status. 
Selection criteria: Prospective and/or retrospective studies that examine the effect of antico-
agulant and antiplatelet drugs on the clinical course of chronic subdural hematoma. Data col-
lection and analysis: The author was the main data collector and investigator from the identi-
fied studies. The data needed extracted for analysis. We collected data related to the outcome 
of subdural hematoma and anticoagulation drugs from the included studies. Two reviewers 
independently checked the eligibility, study selection, methodological quality, risk of bias and 
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extracted data. They also independently assessed the risk of bias assessments for the included 
studies according to the Cochrane Handbook for Systematic Reviews of Interventions. The 
authors of the study were contacted for missing information when possible. We pooled results 
of clinically and statistically homogeneous studies, where possible, to provide estimates of the 
effect of antiplatelets and anticoagulants. Then, we undertook separate subgroup analyses and 
meta-analysis for recurrent subdural hematoma only. We also calculated the risk ratios (RR) 
with 95% confidence intervals (CI). Any disagreements were managed by consensus after 
discussion among the author, the independent reviewers and the supervisors. 
Main results: no randomised controlled trials were identified. We included eleven clinical 
cohort studies involving 1854 and 365 participants for the recurrent and bilateral categories, 
respectively. There was a significant increase in the risk of antipalatelets, with a pooled rela-
tive risk of 1.88. However, the pooled relative risk of anticoagulants was only 1.26 and it was 
not statistically significant.  
Authors’ conclusions: formal recommendations can be made about the proper use and regular 
follow up of antiplatelets in patients. Anticoagulants do not significantly affect recurrent 
chronic subdural hematoma. Non-controlled studies usually come up with conflicting results. 
Therefore, further work is required in order to establish any potential effect of the new and old 
anticoagulation medications on the clinical course of chronic subdural hematoma. There is a 
need for well designed randomised controlled trials and prospective studies with large sample 
sizes and stratification of the different types of anticoagulation drugs investigating the role of 
antiplatelets and anticoagulants on chronic subdural hematoma. 
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The use of the terms ‘‘anticoagulation’’ and ‘‘anticoagulant’’ are used differently in this review. 
The term anticoagulation is used as a descriptive expression for both antiplatelet and antico-
agulant drugs. However, the term anticoagulant is used to describe a substance that prevents 
clotting of blood, such as warfarin, heparin and other similar class of pharmaceuticals.
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1. Introduction 
1.1 Background  
Chronic subdural hematoma (CSDH) is one of the most commonly admitted conditions to 
the neurosurgical unit. It was first described by Wepfer in 1656. It refers to a slowly 
growing encapsulated collection of blood and its breakdown products between the dura 
mater and the arachnoids in the subdural space (1, 2). The incidence of this condition 
increases greatly with age, it is about 1 to 2 per 100,000 individuals per year aged over 60, 
while that in individuals aged over 70 is 7.4 per year (3). Virchow postulated that a 
pachymeningitis hemorrhagica interna was the origin of chronic subdural hematoma in 
1857 (4). Half a century later, in 1914, Trotter considered the bleeding to be of traumatic 
and venous in origin. His theory became increasingly accepted, even for patients with 
inapparent trauma, and it remains the accepted cause for most patients (5). Therefore, the 
current literature identify the likely cause as that subdural hematomas arise from the 
tearing of bridging veins as a result of brain atrophy, and ⁄ or weakness of venous walls in 
elderly patients. Cortical bridging veins are thought to be under greater tension as the brain 
gradually shrinks from the skull; even minor trauma may cause one of these veins to tear.  
(6-8). A history of head trauma is identified in 80% of patients, and in most cases the 
trauma is mild (9, 10). Hematoma thickness tends to be larger in older patients due to a 
decrease in brain weight and increase in subdural space with age (3). In patients older than 
50 years, the mass of the brain is reduced by approximately 200 g, which results in an 
increased extracerebral volume of up to 11%. This extra volume can be occupied by the 
haematoma before a considerable rise in intracranial pressure occurs. In addition, a 
slowly progressing haematoma allows the brain to adjust to the new situation by com-
pressing the venous channels, thus providing further space for the haematoma to expand 
(10). Classically chronic subdural hematomas contains motor motor oil fluid which does 
not clot (11). When the subdural fluid is clear, the collection is termed a subdural hy-
groma (12). Clinical presentation differs widely within the patient groups, ranging from 
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asymptomatic to decreased cognitive functions, severe neurological deficits or even 
life-threatening herniation (2, 13-15). If a haematoma has formed within the subdural 
space, it can be maintained by anticoagulative treatment, ethylism or haematological dis-
orders (3, 16-21). The reasons why this type of hematoma occurs frequently among the 
elderly include an increase in antithrombotic medications, venous fragility, augmentation 
of the subdural space, and an increased exposure to traumatic injury resulting from fre-
quent falls (14). 
Many chronic subdural hematomas probably start out as acute subdural. Blood within the 
subdural space evokes an inflammatory response. Within days, fibroblasts invade the clot, 
and form neomembranes on the inner (cortial) and outer (dural) surface. This is followed 
by ingrowths of neocapillaries, enzymatic fibrinolysis, and liquefaction of blood clot. 
Fibrin degradation products are reincorporated into new clots and inhibit hemostasis. The 
course of chronic subdural hematomas is determined by the balance of plasma effusion and 
/ or rebleeding from the neomembranes on the one hand and reabsorption of fluid on the 
other (22).  
Definitive diagnosis of chronic subdural hematoma relies on computed tomography (CT) 
imaging of the head. On a CT scan, subdural hematomas are classically crescent-shaped, 
with a concave surface away from the skull. However, they can have a convex appear-
ance, especially in the early stage of bleeding. This may cause difficulty in distinguishing 
between subdural and epidural hemorrhages. A more reliable indicator of subdural hem-
orrhage is its involvement of a larger portion of the cerebral hemisphere since it can cross 
suture lines, unlike an epidural hemorrhage (12). Associated membranes may enhance 
with intravenous contrast, which can be useful in preoperative planning (23). Neurosur-
geons are quite familiar with the condition and many of them consider symptomatic 
chronic subdural hematoma prompt specialized evaluation and neurosurgical intervention 
by surgical decompression often on an emergency basis. The majority of patients have 
good outcome after surgical treatment of chronic subdural hematoma. Following surgical 
treatment, 80 to 90% of the patients recover their premorbid function (24-26). Despite, 
complications like wound infection, subdural empyema, tension pneumocephalus, brain 
10 
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contusion, catheter penetration of the brain and even death may occur after surgery (27), 
but recurrent subdural hematoma is the most important complication encountered that 
needs reoperation in the majority of patients as this increases the morbidity and mortality 
of the individual (28). In asymptomatic patients, or patients with relatively small hema-
tomas conservative management with nonoperative measures, such as, hypertonic or hy-
perosmolar solutions and systemic glucocorticoids have been used in CSH with favourable 
results (22, 29, 30). Using relatively simple and safe procedures a neurosurgeon can initiate 
often dramatic improvement in the patient’s condition. However, not all patients improve 
and recurrence is again a major consideration. 
1.2 Burden of the problem 
Chronic subdural hematomas in patients treated with anticoagulant account for 5% of all 
CSDHs (31). According to a recent retrospective review, anticoagulants significantly 
increase the risk of developing chronic subdural hematoma up to 42.5 times, relative to the 
general population (32). In another studies, 41% (33) and 24% (34) of all chronic subdural 
hematoma patients admitted were anticoagulated. Compared with 
non-anticoagulation-related hematomas, the risk of haemorrhage was calculated to be 
increased fourfold in men and thirteen fold in women (34). Recurrent bleedings imply 
recurrence of mass effect which causes clinical symptoms, such as headaches, decreased 
level of consciousness as well as focal disorders, e.g. motor weakness, dysphasia or partial 
amnesia (7, 35, 36). This recurrence can result in reoperation with all the complications 
related to surgery as well as those associated with the general anaesthesia (37). There is a 
clinical improvement when the subdural pressure is reduced to close to zero which usu-
ally occur after approximately 20% of the collection is removed (10). Residual subdural 
fluid collections after treatment are common, but clinical improvement does not require 
complete resolution of the fluid collection on computed axial tomography. The scans 
showed persistent fluid in 78% of cases on post-op day 10, and in 15 % after 40 days (26), 
and may take up to 6 months for complete resolution. It is recommended not to treat per-
sistent fluid collections evident on scan. Especially before 20 days post-op, unless it in-
11 
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creases in size on computed tomography or if the patient shows no recovery or deterio-
rates (12). 
Although the majority of chronic subdural hematomas resolve following a single neuro-
surgical intervention, chronic subdural hematoma (CSDH) has been reported to have a 
substantial recurrence rate ranging from 9.2 to 26.5% (37-42). The risk factors for recur-
rence are thought to be the following: old age, poor performance status at admission, 
cerebral atrophy, large hematoma, alcohol ingestion, usage of anticoagulants, renal failure, 
liver dysfunction, septum formation in the hematoma, and meningeal dissemination of 
malignant tumor (42-45). Although several articles reported antiplatelet and anticoagulant 
related recurrence, others studies have not disclosed any significant results (46-49). 
Bilateral subdural hematoma cases were infrequently experienced and little is known about 
them (50) except that they might be related to the coagulofibrinolytic abnormalities (51). 
Although chronic subdural hematoma is a common occurrence, data on bilateral chronic 
subdural hematoma are scarce compared to the studies on the unilateral ones. Bilateral 
chronic subdural hematoma makes up 16% to 20% of chronic subdural hematoma cases 
(45), especially those older than 75 years (52) and those with coagulation abnormalities 
(51). Furthermore, bilateral chronic subdural hematoma has been considered to be a risk 
factor for recurrence of chronic subdural hematoma in previous studies (45, 53). The bi-
lateral hematomas cases might show rapid and progressive aggravation and should be 
treated as early as possible, within 19 to 54 hours. Kurokawa et al., showed that 6 of 14 
bilateral hematomas cases seemed to show the tendency for a rapid and aggressive clinical 
course, which often resulted in a poor prognosis or residual neurologic deficits (54), he 
concluded that bilateral cases should be treated as early as possible with simultaneous 
decompression of bilateral hematoma pressure, even if the patient shows minimal neu-
rologic deficits.        
The mortality rate of anticoagulant-related subdural hematoma can be high up to 13 % and 
20% (34, 55). The impact of subdural hematoma is not only on the morbidity and mortality 
aspects but also on the economic side, as the mean duration of hospital stay of patients with 
12 
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subdural hematoma usually ranges from 7 to 24 days (31), and the cost totalled $10,670 
(range $907-238,856) per patient (56). 
Because the risk of bleeding is increased while on anticoagulation, the first aim must be 
to reduce unnecessary use of anticoagulants. A lot of patients could not remember their 
medication and forget to mention especially antithrombotic therapy, which they often 
took to reduce symptoms of headache or influenza. 
This is important as the age population is expected to rise; therefore the incidence of 
subdural hematoma is projected to increase over the years. This increasing incidence of the 
disease call for better health service provision by understanding the pathophysiology of the 
disease.  
1.3 Anticoagulation 
However, anticoagulants and antiplatelets are proved to be beneficial in many other con-
ditions such as cardiac conditions, diabetes and many vascular conditions (57, 58), but this 
comes at the expense of increasing the incidence of chronic subdural hematomas (59). Oral 
anticoagulant therapy (OAT) is prescribed to large numbers of patients for the prevention 
and treatment of thromboembolic disease (60). The main use of anticoagulants is to pre-
vent thrombus formation or extension of an existing thrombus in the slower-moving ve-
nous side of the circulation, where the thrombus consists of a fibrin web enmeshed with 
platelets and red cells. Anticoagulants are of less use in preventing thrombus formation in 
arteries, for in faster-flowing vessels thrombi are composed mainly of platelets with little 
fibrin (61).  
Many drugs are known to be used with favourable outcomes to the conditions indicated.  
The oral anticoagulants warfarin, acenocoumarol and phenindione, antagonise the effects 
of vitamin K, and take at least 48 to 72 hours for the anticoagulant effect to develop fully; 
warfarin is the drug of choice. If an immediate effect is required, unfractionated or low 
molecular weight heparin must be given concomitantly. Warfarin act by inhibiting the 
synthesis of the vitamin K dependent clotting factors (Factors II, VII, IX, and X) and 
regulatory proteins (proteins C, S, and Z) at the therapeutic dosages they decrease factors 
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II, VII, IX and X by approximately 30% to 50%, as a result, decreased thrombin is gener-
ated and decreased cross-linked fibrin polymer is formed (61). Consequently a defective 
clotting formation occurs. Subsequently, the cross-linked fibrin polymer is, slowly but 
continuously, degraded by plasmin to form fibrin degradation products which act by in-
hibiting the formation of the stabilizing crosslink bonds in soluble fibrin, resulting a greater 
tendency to rebleed (62). Warfarin has a narrow therapeutic index; thrombosis risk in-
creases when the international normalized ratio (INR) falls below 2.0 and serious bleeding 
risk increases when the INR rises above 4.0. As a result, major bleeding is a common 
problem in people taking OAT, occurring at a rate of 2.4%–8.1% per patient-year (63). 
Heparin is a parental anticoagulants and it initiates anticoagulation rapidly but has short 
duration of action. It is often referred to as standard or unfractionated heparin to distinguish 
it from the low molecular weight heparins which have a longer duration of action. Al-
though a low molecular weight heparin is generally preferred for routine use, unfraction-
ated heparin can be used in those at high risk of bleeding because its effect can be termi-
nated rapidly by stopping the infusion (61). Heparin acts at multiple sites in the normal 
anticoagulation system inhibiting both extrinsic and intrinsic pathways. Heparin in com-
bination with antithrombin III inactivates the activated factor X and the thrombin. Fur-
thermore, heparin prevents the formation of stable fibrin clot by inhibiting the activation of 
the fibrin stabilizing factor (61). In addition to its use for deep venous thrombosis, for 
pulmonary embolism, and in patients after thrombolytic therapy for myocardial infarction, 
heparin is used during invasive angiographic procedures and cardiopulmonary bypass to 
prevent thrombus formation.  
Anitiplatelet drugs decrease platelet aggregation and thrombus formation in the arterial 
circulation, because in faster-flowing vessels, thrombi are composed mainly of platelets 
with little fibrin (61). Antiplatelet agents, in particular aspirin and clopidogrel, are an 
essential component of treatment and prophylaxis for both cardiovascular disease and 
cerebrovasular; however, they are both associated with a small risk of intracranial hem-
orrhage (ICH). Clopidogrel effectively inhibits ADP-induced platelet activation and ag-
gregation by selectively and irreversibly blocking the P2Y 12 receptor on the platelet 
membrane. Interaction of ADP with the P2Y1 receptor of the platelet induces platelet 
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shape change, reversible aggregation, initial glycoprotein IIb/IIIa activation, phospholi-
pase C activation, and calcium flux. Clopidogrel is selective non-competitive inhibitors of 
the P2Y12 receptor. Regular use of clopidogrel (75 mg daily) can produce 40%–50% 
inhibition of ADP-induced platelet aggregation (64). Aspirin acts by irreversibly acety-
lating the cycloxygenase (COX-1) enzyme, thus suppressing the production of throm-
boxane A 2 (TxA 2) and inhibiting platelet activation and aggregation. This represents the 
best-characterized mechanism of action, which fully accounts for the unique pharmaco-
dynamics of aspirin as an antiplatelet agent and adequately explains the saturability of its 
cardio-protective effects (65). The effect of aspirin and clopidogrel on platelets lasts 
throughout the platelet life span, for about 7 days; therefore, in patient platelet aggregation 
tests yields abnormal results on admission. Later on, aggregation tests normalized due to 
transfused platelets and platelets formed de novo in the body (61). 
1.4 Why it is important to do this review: 
The aim of this systematic review is to critically appraise and summarise existing infor-
mation of the effectiveness of anticoagulants/antiplatelets on the clinical outcome of 
subdural hematoma and to identify areas where further research is needed. The first issue 
is, whether intracranial bleeds and anticoagulation treatment occur together by chance or if 
these drugs increase the risk of recurrent and bilateral subdural hematomas. Based on the 
currently available literature, different studies have different results. A review of the lit-
erature has failed to identify a single systematic study and met-analysis of anticoagulation 
related drugs and recurrent and/or bilateral subdural hematomas, and thus no recommen-
dations can be made regarding the effects of anticoagulation in patients with chronic 
subdural hematoma. All the current available literatures are from scattered clinical case 
control studies or cohort studies published previously. Therefore, data about anticoagulants 
and/or antiplatelets and quality of anticoagulation are often incomplete and divergent and 
consequently do not allow for any conclusions individually to be drawn. The present re-
view aimed to fulfil this need. 
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Addressing these issues is crucial as rapid restoration of maximum health potential, espe-
cially in the elderly patients, is vital if a chain reaction of medical complications and as-
sociated economical consequences are to be averted. 
1.5 Aims and objectives 
The aim of the study is to perform a systematic review and meta-analysis of studies that 
examine the effect of anticoagulants/antiplatelets on the clinical course of chronic subdural 
hematoma and to define groups at high risk for recurrent and bilateral subdural hematoma 
and thus to contribute to the prevention of these events in patients receiving anticoagu-
lants/antiplatelets treatment. The study also highlights the issue of sensible use of antico-
agulants and antiplatelets in medical practice as well. To the best of our knowledge, this is 
the first systematic review and meta-analysis. 
We Used the PICO method to formulate our clinical question: 
• Population: all studies about patients with chronic subdural hematoma 
• Intervention: all studies about patients with chronic subdural hematoma on anti-
coagulants/antiplatelets  
• Control: all patients with chronic subdural hematoma not on anticoagulants/ anti-
platelets 
• Outcome: recurrent or bilateral chronic subdural hematoma in patients on pe-
rioperative anticoagulantion 
• The study design is systemic review and meta-analysis of clinical cohort studies 
• Primary outcomes:  
• Recurrent chronic subdural hematoma 
• First presentation of bilateral chronic subdural hematoma 
• Secondary outcomes 
• To identify those patients on anticoagulation with unknown indications 
• To identify the time period between first and second operation. 
• To identify the time period between trauma and first operation 
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• To identify the mortality rate in both recurrent and bilateral groups 
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2. Materials & Methods 
2.1 Research protocol 
The PRISMA guidelines (Appendix 1) for reporting of the systematic reviews and 
meta-analysis were followed to conduct this review. We aimed to identify all studies that 
examined recurrent and bilateral chronic subdural hematoma related to anticoagulation 
drugs. 
We defined recurrent chronic subdural hematoma as the increase in the volume of the 
subdural hematoma on the ipsilateral or contralateral to the operated side as seen on CT 
scan within 6 months of the original drainage procedure and / or occurrence of signs and 
symptoms attributable to the hematoma seen on CT scan within 6 months of the original 
drainage procedure. On the other hand, bilateral chronic subdural hematoma as the oc-
curence of the hematoma on both sides. 
Our review protocol consisted of the detailed research question, search strategy, screening 
criteria for titles and abstracts, and screening criteria for full-text articles. The detailed 
research question was structured using the patient, intervention, comparison, outcome, 
study design (PICOS) approach. Our PICOS research question was formulated as follows: 
does antiplatelet and / or anticoagulant affect the course of subdural hematoma? 
Search databases were Medline (using PubMed, Medline at Ovid Online), EMBASE, 
Scirus, the Cochrane Library, the American Association of Neurological Surgeons 
(AANS) Database, the conference proceedings of the European Association of Neurosur-
gical Societies (EANS) and the Google scholar (http://scholar.google.com). Search queries 
were optimised for each specific database. Searches were also carried out on online clinical 
trial registers; ClinicalTrials (http://clinicaltrials.gov) and Current Controlled Trials 
(http://controlled-trials.com/mrct). We handsearched relevant journals and contacted re-
searchers. 
After deleting duplicate records, titles and abstracts were screened and included if they 
represented studies of patients with bilateral and recurrent chronic subdural hematoma on 
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perioperative antiplatelet and /or anticoagulant. Studies that specifically reported on other 
causes of bleeding disorders were excluded.  
The PICOS research question was the foundation for study selection, without restriction on 
publication date, length of follow-up, or publication status. The search also includes 
studies in other languages with English language abstracts. If anything really useful is 
identified, it can usually be translated. A manual search of references from the identified 
papers was then also performed to yield additional papers. We contacted experts in the 
field and the authors of the identified studies in an effort to identify published, unpublished 
and ongoing studies. 
2.2 Search methods for identification of studies 
We used PubMed, Medline and Scirus as our primary data source, and included “subdural 
hematoma” as a medical subject heading (MeSH) to search with maximum sensitivity. We 
also searched web-based sources using the search engine Google.com. General internet 
searches were carried out using selected terms from the original search strategy and indi-
vidual drug names. Other databases were searched to find additional literature on subdural 
hematoma such as the Google scholar, Google scholar is also used to find papers that cited 
the index papers; however, only “subdural hematoma” turned out to be a valid thesaurus 
term (Medline) or useful keyword (Cochrane Library). Other keywords were queried in-
dividually and/or in combination. Details of the search keywords used can be found in 
Appendix 3. Both English and American spellings were considered. All papers presenting 
the clinical data regarding the outcome from patients with chronic subdural hematoma on 
antiplatelet and / or anticoagulant were selected.  
2.3 Selection of studies 
The author (AE) was responsible for identification and handsearching of appropriate 
studies for consideration. After screening the database search results, full-text assessment 
was done for study selection. Two reviewers (AA, MA) independently checked the studies 
identified by the search strategy to identify potentially suitable studies for the review ac-
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cording to the criteria outlined above and eliminate irrelevant studies. Eligible studies will 
be read fully in duplicate and there suitability for inclusion will be independently checked 
by both reviewers. We resolved disagreements by discussion with the supervisors (CB, 
RC) and the outcome of the discussion then managed by consensus. The author assessed 
the full papers for the type of participants, the type of anticoagulant used, methodological 
quality, the number of patients excluded or lost to follow up, and the secondary outcome 
measures stated in the protocol. We excluded publications that clearly did not meet the 
inclusion criteria at this stage. We retrieved and reviewed the full text of the selected arti-
cles and translated in to English where required. 
2.4 Data Extraction and management 
The author firstly extracted the data into an extraction sheet (Appendix 4). The review 
authors would have independently checked the extracted data. Any disagreement at any 
time would have been resolved by discussion among the review authors. After consensus, 
the author transferred the data to a Microsoft excel datasheet (version 2007 for Windows). 
Data collection items were extracted into categories. We planned to extract the required 
information from each included study. As defined in the protocol, data on the following 
variables were extracted from the selected studies: study design parameters, year of data 
collection, number of patient on anticoagulants, number of patient not on anticoagulant, 
number of recurrences in patients on anticoagulant, number of recurrences in patients not 
on anticoagulant, mortality, unknown indications of the anticoagulation medications, pe-
riod between the first operation and reoperation, and period between trauma and first op-
eration. The summary of the findings tables will include comparisons between the patients 
on and not on anticoagulants/antiplatelets. The authors of the selected articles were con-
tacted by emails for any additional data required for the review and information regarding 
any other studies can be included, they are aware of.  
Meta-analysis planned after discussion with the methodology supervisor. We have labelled 
warfarin, heparin, and related drugs as anticoagulant; aspirin and clopidrogel are catego-
rized as antiplatelet to simplify the analysis. 
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No external fund is received for the systematic review. To the best of our knowledge, no 
similar meta-analysis and systematic review has been performed previously. All the 
studies were carefully scrutinized for inclusion and exclusion criteria. 
2.5 Types of studies 
All studies comparing respectively the outcome of chronic subdural hematoma caused by 
anticoagulant and/or antiplatelet. 
2.6 Types of participants 
2.6.1 Inclusion criteria 
• Prospective, retrospective studies and cross-sectional studies. 
• All studies that examine the effect of perioperative anticoagulant and / or anti-
platelet treatment on the clinical course of chronic subdural hematoma. 
 
We planned to include patients without age, sex, or both spontaneous and trauma patients 
restrictions. Studies not fulfilling these basic criteria were reviewed to identify other 
suitable studies but excluded from the analysis. 
2.6.2 Exclusion criteria 
We excluded from the analysis all the participants of the studies who have history of 
bleeding disorders or bleeding causes other than anticoagulation therapies. Recurrent 
subdural hematoma patients in the contest of bilateral subdural hematomas were also ex-
cluded from the study. 
2.6.3 Population 
All studies about patients with chronic subdural hematoma 
2.6.4 Intervention 
All studies about patients with chronic subdural hematoma on anticoagulant/antiplatelet 
2.6.5 Control 
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All patients with chronic subdural hematoma not on anticoagulant/antiplatelet  
2.7 Types of outcome measures 
2.7.1 Primary outcomes 
• Recurrent chronic subdural hematoma 
• First time presentation of bilateral chronic subdural hematoma. 
2.7.2 Secondary outcomes 
• To identify those patients on anticoagulation with unknown indications 
• To identify the time period between the first and second operation. 
• To identify the time period between trauma and first operation 
• To identify the mortality rate in both the recurrent and bilateral categories 
2.8 Potential confounders  
Bilateral subdural hematoma is itself a risk factor for developing recurrent subdural he-
matoma. Any study reporting recurrence in the contest of bilateral subdural hematoma is 
excluded from the recurrent group. 
2.9 Data collection 
See appendix 5 for data collection sheet. 
2.10 Data collection procedure 
• The author/investigator was the main data collector from the studies  
• Missing data were handled by contacting the authors of the index papers and 
more search for other studies to be included using the criteria outlined above 
2.11 Data protection 
• All relevant information in this study were handled in line with data protection 
rules 
22 
 
 
 
The contents of the enclosed manuscript are confidential and should not be disclosed, or disseminated in any way, to any third party 
other than to staff or students of the Royal College of Surgeons in Ireland or an external examiner appointed for the purpose of reviewing 
the manuscript. 
• No ethical approval was needed for this study. The study protocol was in accor-
dance to the guidelines of the ethics committee at our university, Royal college of 
Surgeons in Ireland. 
• Informed consent is not required in our study as all our data were collected from 
published articles. However we did ensure patient’s anonymity was maintained 
during our contact with authors for missing data. 
2.12 Assessment of risk of bias 
We investigated also any sources of bias. We intended that at least two authors will assess 
the internal validity of individual trials, using the Cochrane Collaboration’s risk of bias 
tool as described in the Cochrane Handbook for Systematic Reviews of Interventions 
(Higgins 2008). Using the data extraction sheet developed for this review, the author ex-
tracted relevant data and this was compared and discussed with the reviewers until con-
sensus was achieved and a recommendation made for inclusion or exclusion from the 
review. We entered details in a risk of bias table designed by the author and adopted from 
the Cochrane handbook (Appendix 5), for each included study, indicating the methodol-
ogy, mainly concentrating on the stratification of the author of the article for the other 
different causes of bleeding disorders, other selection bias, performance bias, attrition 
bias, detection bias and confounding factors, and reporting bias. Two reviewers (MA and 
AA) independently evaluated the risk of bias of the included studies. The risk of bias in 
each domain was rated as high risk, low risk, and unclear. Any disagreement again be-
tween the reviewers was resolved by consensus. 
2.13 Assessment of heterogeneity 
Before pooling any data for analysis, we considered whether or not there was substantial 
clinical heterogeneity between the studies. We planned to examine the participants, in-
terventions, and outcomes of the studies for evidence of clinical heterogeneity. We ex-
plored heterogeneity and performed subgroup analyses as appropriate. We considered 
subgroup analysis by different types of drugs. However following consideration of the 
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data available from the included studies we only performed subgroup analysis into the 
types of anticoagulation for recurrent hematomas. If heterogeneity encountered, we 
would have inspected the outlier studies to determine the cause. If clear reasons for the 
heterogeneity were found, we would not have added the responsible studies to the main 
body of homogeneous studies, but would have summated and presented them separately 
and indicated the reasons for heterogeneity. Additionally, we would have used the 
I-squared statistic to quantify the extent of heterogeneity. This provides an estimate of the 
percentage of variability due to heterogeneity rather than chance alone. If the I-squared 
estimate was greater than 50%, we would have interpreted this as indicating the presence 
of considerable levels of heterogeneity. We planned that if there was any evidence of 
clinical or statistical heterogeneity; we would not conduct a meta-analysis and would 
report findings in a narrative form. Then, we considered the appropriateness of pooling 
and meta-analysis was performed. 
2.14 Statistical analysis 
All statistical analysis was performed using the StataIC 12 software for Windows 
(StataCorp College station, Texas, USA). Throughout the analysis, a p-value of less than 
0.05 was considered significant. To identify risk factors for the development of recurrent 
and bilateral chronic subdural hematoma, we calculated relative risk ratios (RR) and cor-
responding 95% confidence intervals (CI).  
3. Results 
All studies included in this review were clinical cohort studies comparing respectively the 
outcome of chronic subdural hematoma caused by anticoagulant and/or antiplatelet. 
3.1 Study Identification 
A PRISMA 2009 flow diagram is followed for the search strategy (Figure 1, Appendix 2). 
The search strategy yielded 157 of articles, of which 104 were excluded based on title or 
abstracts. Fifty one full text articles where assessed for eligibility. Only 11 articles of the 
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remaining fifty one articles met our inclusion criteria and were included in the systematic 
review. 
3.2 Study characteristics 
The search strategy yielded a total of eleven studies that fit the above criteria. Three 
studies are based in Japan (27, 28, 47), two in Germany (48, 66), one in the united king-
dom (49), one in Australia (32), one in Ireland (46), one in Korea (67), one in France 
(68), and one in Taiwan (69). Nine studies for the recurrent subdural hematoma (Table 1) 
and two studies for the bilateral groups (Table 2). There is a broad international variation 
in the countries where the studies took place.                                                               
The size of participants in the included bilateral studies ranges from 129 (67) to 236 (68) 
participants, and for the recurrence ones from 81(32) to 500 (27) participants. In total, 
1854 and are included in the meta-analysis for the recurrent. No meta-analysis was at-
tempted for bilateral subdural hematomas. 365 patients were studied for the bilateral 
category. All the eleven studies used the same study design to identify the patients. One 
study was in French language with English abstract. Translation was done with the help 
of Google translator and contacting the experts in French language. Of these eleven re-
quests sent to the author of the studies, none were answered at the time of writing the 
thesis. The summary of the findings include comparisons between the recurrent hematoma 
patients on and not on anticoagulant/antiplatelet groups (Table 3, Table 4). 
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Figure 1. PRISMA flow diagram of search strategy. 
 
 
 
 
 
 
Table 1. Included studies of the recurrent subdural hematoma 
The study Study year Type of the study Number of patient studied 
O'Brien et al. (46) 1994-1997 Clinical Cohort Study 123 
Buxton et al. (49) 1990-1992 Clinical Cohort Study 34 
Buxton et al. (49) 1995-1997 Clinical Cohort Study 150 
Konig et al. (48) Two years period Clinical Cohort Study 114 
Forster et al. (66) Consecutively admitted patients Clinical Cohort Study 144 
Byung et al. (67) 2001-2006 Clinical Cohort Study 255 
Torihashi et al. (47) 2003-2007 Clinical Cohort Study 337 
Rust et al. (32) 1996-2001 Clinical Cohort Study 81 
Oishi et al. (28) 1995-1999 Clinical Cohort Study 116 
Mori et al. (27) 1987-1999 Clinical Cohort Study 500 
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Table 2. Included studies of bilateral subdural hematoma 
The study Study year Type of the study Number of patients studied 
Tsai et al. (69) 2002-2005 Clinical Cohort Study 129 
Penchet et al. (68) 1990-1995 Clinical Cohort Study 236 
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Table 3. Summary of the data of recurrence on anticoagulant 
The study 
Number of patients 
studied 
Anticoagulant 
Patient not on 
anticoagulant 
Patient on 
anticoagulant
Recurrence off 
anticoagulant 
Recurrence on 
anticoagulant 
O'Brien et al. 123 Anticoagulant 30 15 2 3 
Buxton et al. 184 Anticoagulant 150 34 22 5 
Forster et al. 144 Anticoagulant 40 66 0 22 
Byung et al. 255 Anticoagulant 247 8 18 1 
Konig et al. 114 Anticoagulant 84 21 16 2 
Rust et al. 81 Anticoagulant 46 17 8 2 
Torihashi et al. 337 Anticoagulant 275 11 47 2 
Torihashi et al. 337 Both* 275 13 47 2 
Oishi et al. 116 Both* 105 11 6 0 
Mori et al. 500 Both* 474 26 23 9 
* anticoagulant & antiplatelet
  
Table 4. Summary of the data of recurrence on antiplatelet 
The study 
Number of 
patients studied 
Anticoagulant
Patient off 
antiplatelet 
Patient on 
antiplatelet 
Recurrences 
off antiplatelet
Recurrences 
on antiplatelet
O'Brien et al. 123 Antiplatelet 30 78 2 10 
Forster et al. 144 Antiplatelet 40 38 0 12 
Konig et al. 114 Antiplatelet 84 9 16 2 
Rust et al. 81 Antiplatelet 46 18 8 7 
Torihashi et al. 337 Antiplatelet 275 38 47 10 
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Table 5. Summary of the data of bilateral chronic subdural hematoma 
The Study 
Number of 
patients studied 
Anticoagulation
Patient off 
anticoagulation
Patient on  
anticoagulation 
Bilateral not on 
anticoagulation
Bilateral on 
anticoagulation
Tai et al 129 Both* 118 11 44 11 
Penchet et al 236 Both* 179 57 40 9 
* anticoagulant & antiplatelet
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3.3 Risk of Bias 
Low risk of bias was identified in the included studies for the recurrent subdural hematoma. 
We did not do any analysis for the bilateral subdural hematoma because all the studies of the 
bilateral category encountered did not specify the types of the anticoagulation drugs used. In 
the recurrent subdural category, three studies failed to report the type of anticoagu-
lant/antiplatelet drug used, and they are excluded from the analysis of the homogenous 
groups. The analysis of these three studies was presented separately (Figure 1).  
3.4 Effects of intervention 
3.4.1 Recurrent Subdural Hematoma 
The analysis of antiplatelets shows a significant increase in risk, with a pooled relative risk of 
1.88, and no significant heterogeneity between studies (I-squared = 26.5%, p = 0.245). For 
anticoagulants, however, the pooled relative risk was only 1.26 and it was not statistically 
significant. Again, there is no significant heterogeneity (I-squared = 40.8%, p = 0.119). Fi-
nally, the studies that failed to distinguish between the antiplatelets and anticoagulants show a 
mixed picture, with significant heterogeneity (I-squared = 83.0%, p = 0.003). This is impor-
tant because it can explain that the effect would depend on the precise admixture of the two 
treatment regimes. The Overall outcome of the recurrent subdural hematoma I-squared is 
58.6%, and p-value equal to 0.002. The heterogeneity is encountered when we combined the 
both data of the anticoagulant and antiplatelet drugs together into one category, but this is 
solved by stratification the data of the medications into two subgroups after careful reviewing 
the design of the studies included in the review (Figure 2). 
3.4.2 Bilateral subdural hematoma 
Regarding the bilateral subdural hematoma, the included studies did not differentiate between 
the anticoagulant and antiplatelet drugs. The analysis shows a significant increase in risk, with 
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 a pooled relative risk of 1.34 (p = 0.000) (Figure 3). The overall I-squared was 96.8% and this 
indicates significant heterogenity. Given the lack of high-quality studies and the heterogeneity 
of the data from the available studies pointing to the possibility of bias, we did not perform 
meta-analysis for the bilateral category. Out of the 129 patients studied retrospectively by Tai 
eleven were received anticoagulation medications. Bilateral was noted in all of them. How-
ever, in the retrospective analysis of Penchet nine patients developed bilateral subdural he-
matomas of the 57 participants who are on anticoagulant (Table 5). 
3.4.3 Unknown indication of anticoagulation 
The unknown indication of treatment category was defined as when the indication of the an-
ticoagulation treatment was unknown to the patient, the relatives, nor the neurosurgical team. 
Both O’Brien and Buxton reported at different time periods that patients who had no indica-
tion for anticoagulation was approximately 20%. This means that one in every five patient the 
indication of the anticoagulation drugs were unknown (Table 6). 
Table 6. Unknown indication of anticoagulation 
The study Unknown indication of anticoagulant 
O'Brien et al. 24 (20%) 
Buxton et al. 7 (21%) 
3.4.4 Time period to operation and reoperation 
Buxton found that all recurrences of subdural haematoma occurred within 3 weeks of the first 
operation. According to Torihashi et al., the time interval between the injury and the first op-
eration for patients with antiplatelet and/or anticoagulant therapy (29.9 +/- 26.5days) was 
shorter than that for patients without it (44.2 +/- 26.6) (P = 0.022). In contrast, the average 
time between the first operation and the second operation was 33.4 +/- 18.2 days for patients 
who had received antiplatelet and/or anticoagulant drugs, compared with 34.2+/- 24.9 days 
for patients who had not (P = 0.897). Mori in 2001 found that recurrence of hematoma was 
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recognized at 1-8 weeks after the first operation. Furthermore, the interval from trauma to first 
operation was 7.2 +/-3.8 weeks in patients with recurrence and 8.5 +/-5.0 weeks in patients 
without recurrence but this difference was not statistically significant to him (Table 7). 
Table 7. Time period to operation/reoperation of participants 
The study Time to reoperation Time to operation 
Buxton et al. within 3 weeks N/A 
Torihashi et al. 33.4 +/-18.2 days 29.9 +/- 26.5 days 
Mori et al. 1-8 weeks ( Mean: 3.5+/-1.9 weeks) 7.2 +/- 3.8 weeks 
3.4.5 Mortality 
Mori have six patient (1.2%) died in his analysis, Forster five patients (3.5%), Buxton three 
patients (0.02%), Konig four patients (3.5%), and no death for Torihashi in the recurrent 
group (Table 8). However, the bilateral categories, both Tsai and Penchet reported a mortality 
rate of 2 (4%) and 5 (2.6%) patients, respectively (Table 9). 
Table 8. Mortality rate of recurrent chronic subdural hematoma 
The study Mortality rate 
Buxton et al. 3 (0.02%) 
Konig et al. 4 (3.5%) 
Forster et al. 5 (3.5%) 
Torihashi et al. 0 
Mori et al. 6 (1.2%) 
 
Table 9. Mortality rate of bilateral chronic subdural hematoma 
The study Mortality 
Tsai et al. 2 (4%) 
Penchet et al. 5 (2.6%) 
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Figure 2. Meta-analysis of the antiplatelets/anticoagulant related recurrent chronic subdural hematoma 
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Figure 3. Meta-analysis of the anticoagulants related bilateral chronic subdural hematoma 
 
The contents of the enclosed manuscript are confidential and should not be disclosed, or disseminated in any way, to any third party other than to staff or students of the Royal College of Surgeons in Ireland or an external 
examiner appointed for the purpose of reviewing the manuscript. 
36 
 
 4. Discussion 
4.1 Statement of principle findings 
The aim of this review was to evaluate the effects of anticoagulation therapy on the clinical 
course of chronic subdural hematoma, in terms of development recurrent or bilateral subdural 
hematoma. Given the conflicting results regarding the use of anticoagulation related drugs in 
patients with bilateral or recurrent CSH, it is disappointing that there are no randomised con-
trolled trials (RCTs) that evaluated their effectiveness in those patients with chronic subdural 
hematoma. We identified only retrospective or clinical cohort studies. 
The analysis of antiplatelets shows a significant increase in risk, with a pooled relative risk of 
1.88, and no significant heterogeneity between studies (I-squared = 26.5%, p = 0.245). For 
anticoagulants, however, the pooled relative risk is only 1.26 and it was not statistically sig-
nificant. Again, there was no significant heterogeneity (I-squared = 40.8%, p = 0.119). Fi-
nally, the studies that failed to distinguish between the antiplatelets and anticoagulants 
showed a mixed picture, with significant heterogeneity (I-squared = 83.0%, p = 0.003). This 
is important because it can explain the effect would depend on the precise admixture of the 
two treatment regimes. 
4.2 Context of previous studies 
Although our systematic review is the first review assessing the impact of the anticoagulant and 
or antiplatelet on the clinical course of chronic subdural hematoma. Regarding the anticoagu-
lant, our findings are consistent with other studies that showed there was no statistical sig-
nificance in the recurrent group (47-49). Regarding the antiplatelet, our result identified a sig-
nificant result with recurrent. There is some uncertainty as to the impact that aspirin has on the 
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 risk of sustaining intracranial hemorrhage. In two case control studies, aspirin in its usual 
prophylactic dose did not significantly increase the risk of intracerebral bleeding (70, 71). 
Another study found no statistically significant difference in recurrence of hematoma in pa-
tients who did (32%) and did not (13%) receive antiplatelet agents preoperatively (66). 
One review claimed that aspirin would double the risk of intracerebral bleeding, regardless of 
dose (72). This conclusion was reached on the pooled data from four randomized controlled 
trials of combined oral anticoagulant and aspirin use in patients with prosthetic heart valves, 
and may therefore be subject to selection bias. Torihashi et al. restarted antiplatelet medications 
one week after surgical intervention. These authors observed no significant difference in the 
frequency of chronic subdural hematoma recurrence between those patients with a history of 
antiplatelet medications and those without such a history (47). In contrast, a single-center study 
of 81 patients presenting with chronic subdural hematoma who underwent evacuation of their 
lesion found that a significantly higher proportion of patients with a history of aspirin (39%) 
underwent reoperation for recurrent chronic subdural hematoma than did those patients either 
on warfarin (21%) or without any history of anticoagulation/antiplatelet medication (28%) (32).  
It is generally assumed that the prognosis of oral anticoagulant-related intracranial hemorrhage 
is worse than bleeds unrelated to oral anticoagulant use, mainly because of the greater chance of 
extension (73). Six studies found the bleeding risk to be strongly related to the intensity of oral 
anticoagulation, with a RR 1.4–1.8 for every unit increase starting from international 
normalized ratio (INR) 2.0, and a RR 3.0–7.9 for INR ≥4.5 (74-78). Most reports dealing with 
anticoagulant related intracranial hemorrhage have discussed the duration of therapy on the risk 
of bleeding. One opinion is that the risk of an intracranial hemorrhage is increased in the first 
months after starting oral anticoagulant therapy (79-82), while an alternative view states that 
the risk of sustaining an intracranial bleed increases with increasing length of therapy (34, 83). 
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 The proportion of patients found to be overanticoagulated has generally ranged from 6% to 
38% of patients (34, 79, 83-87), while the intensity has also been reported to be ‘subtherapeutic’ 
in up to 28% of patients (34, 80, 87). However, the international normalized ratio values 
determined upon admission do not necessarily reflect the international normalized ratio at the 
time of sustaining a haemorrhage. Caution is thus warranted when making inferences on the 
risks associated with intensity of oral anticoagulant therapy from INR values measured on 
admission (85). 
Mattle et al. (34) suggest that as many as one-third of patients, having intracranial haemorrhage, 
whilst on warfarin, may not actually need to be on it. Furthermore, a study by Buxton et al.(49) 
showed that seven patients had no indication for warfarin in their notes. 
Mortality varies in the literature between the series from 2% to 4.3% (21, 40, 59, 88). A high 
mortality index in the postoperative period was found in patients with INR (international 
normalized ratio) values greater than 1.25 and/or thrombocytopenia (p<0.001 and p=0.004 
respectively), a mortality of 9.3% of patients treated for this condition (89). One study re-
ported that both overall mortality (OR = 4.48, 95% CI 1.60-12.50, p = 0.004), and mortality 
after Intracranial haemorrhage (OR = 3.42, 95% CI 1.09-10.76, p = 0.03) was increased in the 
therapeutic as compared with the nonuser group (90). According to the current analysis, the 
mortality in the bilateral group is more than the recurrent subdural hematoma. This is reported 
in previous studies and explains the aggressive course of the disease and the importance of the 
early identification. 
4.3 Strengths and weaknesses 
There is a risk of publication bias in all systematic reviews. In an effort to minimise this we 
searched extensively for relevant literature in databases, handsearched conference abstracts 
and contacted trial authors and experts in the field for unpublished and ongoing trials. We are 
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 confident that our detailed search strategy combined with handsearching identified all relevant 
trials. However, it is still possible that we did not identify some ’grey’ literature. It would be 
unlikely, however, that this would have a significant impact on our results. No statistical or 
graphical evidence for publication bias was detected in the selected articles. 
We have reported the findings of nine studies of recurrent subdural hematoma and two studies 
of bilateral subdural, all of them related to anticoagulation caused by medications and we be-
lieve they were the only published studies that satisfied our inclusion criteria at the time of 
our search. The weakness of this review was the small number of studies included in the 
analyses and the heterogeneity mainly encountered among the bilateral groups due to the lack 
of reporting of the type of anticoagulation drug in the original study. We noted the exclusion 
of several potentially relevant trials solely on the basis that they had not included any clini-
cally relevant outcome measures and absence of control. This limitation considerably reduced 
the power of this review to reach reliable conclusions and we urge future researchers to in-
clude such outcomes in their clinical trials. The strengths of our study are that it addresses a 
question that is potentially of enormous clinical and public health importance using different 
clinical cohort studies. This study pools data from a range of studies from different locations 
and time periods, and therefore enhances the generalisation of its findings. The results of this 
study should be interpreted in the context of the review limitation and scarcity of the available 
relevant studies. Therefore, we recommend that further multicentre studies/trials with larger 
sample sizes be undertaken to evaluate the efficacy of different anticoagulation therapies on 
chronic subdural hematoma. Moreover, the quality of the included studies was measured by 
using a validated method for assessing the quality. In addition, two reviewers independently 
assessed both the quality of the included studies, risk of bias and the data extracted. 
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4.4 Clinical implications 
The two most common conditions requiring chronic anticoagulation are prosthetic heart 
valves and chronic atrial fibrillation. Atrial fibrillation is the most common arrhythmia en-
countered in clinical practice, in prospective studies, the incidence is <0.1% per year in pa-
tients <40 years old and reaches 1.5–2% per year in those >80 years old (91). Mechanical 
heart valves are thrombogenic and require long-term anticoagulant therapy. The incidence of 
prosthetic valve thrombosis in patients not anticoagulated or taking anti-platelet drugs is 1.8% 
per patient / year. The incidence of embolism resulting in death, stroke, or peripheral ischemia 
requiring surgery is 4% per patient / year and this is reduced to 1.0% per patient year with 
anticoagulant therapy (92). 
The most common anticoagulant medication in the literature implicated in the development of 
chronic subdural hematoma is orally administered warfarin (93). Adjusted dose warfarin has 
been shown to reduce stroke incidence by 62% in patients with chronic atrial fibrillation (39). 
This benefit was not offset by the occurrence of major hemorrhage. The rate of intracranial 
hemorrhage is approximately 0.3% per year for patients receiving warfarin with a maintained 
international normalized ratio of 2.0 to 3.0. The rate of stroke among patients with chronic atrial 
fibrillation who are not receiving anticoagulantion ranges from 5% to 12% per year (55, 94). A 
recent meta-analysis showed that adjusted-dose warfarin and antiplatelet agents reduce stroke 
by approximately 60% and by approximately 20%, respectively, in patients who have atrial 
fibrillation. Warfarin is substantially more efficacious (by approximately 40%) than anti-
platelet therapy. Judicious use of antithrombotic therapy importantly reduces stroke for most 
patients who have atrial fibrillation (95). Evidence supports the safety of temporary interrup-
tion of anticoagulation therapy for 1 to 2 weeks in patients with intracranial hemorrhage and 
mechanical valves or atrial fibrillation (96, 97). 
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 Current guidelines for reversal of oral anticoagulant related anticoagulation are the use of vi-
tamin K, FFP, or factor concentrates (34, 98-101). The simplest method of reversal is the 
withholding of 1 or more doses of the vitamin K antagonist. Although the coagulopathy be-
gins to correct within 24 to 36 hours, it will not fully correct for 3 to 5 days; therefore, this 
method is only appropriate for an asymptomatic patient with an elevated INR or a very minor 
bleed (102). The correction may take 9 hours with standard FFP and with factor IX complex 
in conjuncture with FFP it may take 2.93 hours (99). In addition to the time factor, FFP infu-
sion can cause fluid overload as a result of the number units required to reverse anticoagulant 
and the impaired renal and cardiac functions in this age groups (103). Alternative to FFP for 
the reversal of warfarin include prothrombin complex concentrate (PCC), which includes the 
vitamin-K dependent coagulation factors II, VII, IX and X. This permits complete reversal with 
a bolus infusion over a period of three minutes without hemorrhagic or thrombotic adverse 
effect observed intra- or post- operatively (104). Whereas PCC can be rapidly prepared and 
corrects vitamin K antagonist-induced impairment of hemostasis within 30 minutes of 
administration, FFP must be thawed and large volumes infused, leading to delayed and often 
inadequate correction of anticoagulation (102, 103). Prothrombin complex also offers safety 
advantages over FFP, such as virus reduction/inactivation and a low risk of thrombotic events 
(104-106). FFP is associated with transfusion-related lung injury, allergy/anaphylaxis, 
hemolysis, and bacterial contamination/sepsis (107). Another complex used for the reversal of 
oral anticoagulant include recombinant - activated factor VII (rFVIIa), it was used to rapidly 
reverse excessive warfarin induced anticoagulation (108). It appears that rFVIIa may be the 
best candidate to date for reversal of coagulopathy in intracranial hemorrhage (109). This 
agent was found to be helpful in reversal of intraoperative coagulopathy that proves refractory 
to the traditional methods. However, the role of rFVIIa remains unclear given the known side 
effects of thromboembolic adverse events with its extremely high cost (110-112). The sug-
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 gested optimal coagulation parameter at which neurosurgical procedures can be performed is 
an INR of at least 1.4 or less (86, 99). Given the potential for adverse thrombotic events asso-
ciated with reversal of coagulopathy (104, 113), a more gradual reversal technique, such as the 
administration of vitamin K, can be decided in non critical conditions, when initial conservative 
management is planned (114).This is accomplished by administering up to 10 mg of vitamin K 
via slow intravenous infusion, followed by oral supplementation of 1or 2 mg (93). According to 
Boulis et al., he found an accelerated correction of coagulation in the factor IX complex con-
centrate group and a higher complication rate for the FFP-treated group when compared the use 
of fresh frozen plasma (FFP) and factor IX complex concentrate in anticoagulation treated 
patients with intracranial haemorrhage. Another advantage of factor IX complex concentrate is 
the less volume load compared with FFP (99). Heparin and heparin derivatives, on the other 
hand, can be counteracted by protamine sulphate (115). Protamine sulfate irreversibly binds to 
heparin, thereby neutralizing its anticoagulant effect, and is the only drug clinically available 
for this purpose. Used according to established guidelines, protamine is a relatively safe and 
effective drug, but serious adverse reactions may occur. The exact incidence of severe reactions, 
including respiratory compromise, hypotension, and shock, varies from 0.2% to 3% in a general 
population (116). 
Reintroduction of anticoagulation should be based on the balance between a patient’s hrom-
boembolic risk and their bleeding risk. When the risk is equal for both, use of intravenous 
unfractionated heparin may be considered (98). Anticoagulation with enoxaparin after me-
chanical heart valve replacement has been found to provide adequate biological anticoagula-
tion, and compares favourably with unfractionated heparin anticoagulation (117). Enoxaparin, 
a low molecular weight heparin, has been found to be effective and relatively safe substitute 
anticoagulant for patients with mechanical heart valves who must withhold oral anticoagulant 
(118). In the patient with subacute SDH no hematoma expansion was noted during the period 
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 of treatment with unfractionated heparin and nadroparin calcium. In 2010, Forster et al. (66), 
reported the significant increase in the risk of reoperation with the duration and dose of post-
operative application of low molecular weight heparin (nadroparin; molecular weight 4500 
daltons). Of 66 patients were postoperatively treated using LMWH, 22 (33%) had to undergo 
reoperation while the remainder did not, with a median duration of the treatment of 18 days and 
10 days, respectively ( p < 0.01). The daily median dosage of treatment was 5700 IU in the 
patients who required reoperation and 2850 IU for those who did not (p < 0.05). Discontinua-
tion of oral anticoagulant therapy for about 2 to 3 weeks has comparatively a low probability 
of embolic events in patients with mechanical heart valve (109, 119). Strikingly, Wijdicks et 
al. (97) feels that the risks of stopping warfarin for neurosurgical intervention are small even 
for up to 2 weeks. Buxton et al., confirmed stopping warfarin over a shorter period of 3–5 
days without detectable harmful effect (49). One study have showed that failure to achieve 
reversal of anticoagulation preoperatively may be associated with poor outcome (120) . Even 
in patients with compelling indications for anticoagulation such as patients with prosthetic heart 
valves reversing anticoagulation is still necessary, as arresting intracranial bleeding is para-
mount.  
Patients with chronic subdural hematoma who undergo reversal of anticoagulation prior to 
surgical treatment do not experience additional post-operative morbidity and increased rates of 
recurrence relative to patients without a requirement for anticoagulation (121). Both Buxton 
and Kawamata et al., also found that early resumption of anticoagulant therapy (within 3 days) 
did not result in intracranial rebleeding in any postoperative patient. Both authors recommend 
resuming anticoagulants after an interval of 3 days in those patients with mechanical heart 
valves (49, 120). In those patients whose anticoagulant medications were restarted 
post-operatively, recurrence rates ranged from 6% to 10% (49, 120), while in those who were 
not restarted, the rate was 22% (49). Additionally, the rates of thrombotic complications for 
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 patients off anticoagulation (0–10%) did not vary significantly from patients without baseline 
anticoagulation requirements (49, 120). In his experience, Konig et al. (48) described that 
patients under anticoagulative medication, being treated with coagulation factors preopera-
tively, reach an outcome level comparable with those patients without any coagulation disor-
ders. Therefore, it seems to be a benefit to perform subtle correction of anticoagulation before 
surgery.  
Aspirin is the most widely used treatment to prevent cardiovascular disease because it is in-
expensive and highly effective, reducing the risk of myocardial infarction, stroke or cardio-
vascular death by about 20% in a broad range of patients at high-risk of future cardiovascular 
events (122). Most commonly, patients on antiplatelets planned for subsequent evacuation of 
the chronic subdural hematoma undergo reversal of the antiplatelet agents prior to intervention. 
This can be accomplished through platelet transfusion (123) and/or desmopressin administra-
tion (124); however, no studies to date have rigorously analyzed the efficacy of such therapy in 
the setting of chronic subdural hematoma. Recently a study conducted by Li found that platelets 
aggregation recovers within 4 days of stopping aspirin but clopidogrel must be stopped for 10 
days to achieve a normal aggregatory response (125). Use of aspirin in primary prevention of 
cardiovascular events, in patients with or without diabetes, is of unproven benefit. Long-term 
use of low-dose aspirin is of benefit in established cardiovascular disease (secondary 
prevention). On the other hand, it seemed also to increase the incidence of hemorrhagic stroke 
both in the primary and in the secondary prevention trials (126). 
The most efficient way to reduce its occurrence of recurrent or bilateral is to check the indica-
tion for anticoagulant treatment over and over again. On the other hand, the fear of bleeding 
complications should not restrain the physician from antithrombotic therapy, and after haem-
orrhage it should not restrain the physician from restarting the anticoagulant medication fol-
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 lowing an appropriate time period either. Some of the patients do not die because of the in-
tracranial bleed. They die after discontinuation of anticoagulation because of the disease for 
which the treatment was being given. 
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 5. Conclusions 
5.1 Implications for practice 
Anticoagulants do not appear to have an effect on the clinical course of chronic subdural he-
matoma, although more studies need to be done to confirm it. Anticoagulants are effective in 
reducing stroke related to atrial fibrillation and prosthetic heart valves as well as they are 
reasonably reversible. Antiplatelets drugs were found to be significantly affect the outcome of 
subdural hematoma. On the balance, our study recommends the use of anticoagulants compared 
to antiplatelets when indicated. The study also recommends the utmost important of both the 
accuracy of diagnosis and the strength of indication before starting oral anticoagulant therapy. 
The need for regular monitoring of the drug is of course self-evident, and the lowest effective 
target INR for each individual indication should be recommended. In conclusion this study 
emphasis the use and lowest effective anticoagulation for each individual indication should be 
recommended. Clinicians must balance the potential benefit against the risk of complications in 
each case. 
5.2 Implications for research 
There is the need for more well designed prospective and randomized controlled studies to 
explore the issue more thoroughly. It also would be helpful if future studies on anticogualtion 
medications reported the types of drugs involved in the study. More studies are needed to 
investigate the role of classical and new anticoagulants and antiplatelets on chronic subdural 
hematoma. Therefore, our study aims to determine the effect of perioperative anticoagulation 
drugs on the clinical course and postoperative outcome of chronic subdural hematoma patients. 
There is a need for more clinical studies with adequate sample sizes to detect clinically im-
portant differences and using established outcomes to add weight to the results we have ob-
tained. 
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Appendix 2. PRISMA 2009 flow diagram 
 Appendix 3. Search keywords 
1. subdural, chronic/ 
2. subepidural* 
3. hematoma.tw 
4. haematoma.tw 
5. hematom*.tw 
6. haematom*.tw 
7. hemorrhag*.tw 
8. haemorrhag*.tw 
9. subdur* or extracran*.tw 
10. chron*.tw 
11. bleed.tw 
12. anticoagulants.tw 
13. anticoagulan*.tw 
14. anticoagula* 
15. aspirin.tw 
16. warfarin.tw 
17. clopidrogel.tw 
18. heparin.tw 
19. antiplatelet* 
20. pachymening*  
21. extracran* 
22. Anticoaguls* or antiplate* 
23. randomized controlled Trial, controlled clinical trial.tw 
24. clinical trial.tw 
25. vitamin K antagonist.tw 
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27. antithrombin.tw 
28. low molecular weight heparin 
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30. enoxaparin.tw 
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Appendix 4. Data collection sheet  
The Study   
The year  
Patients studied  
Drug type  
Patients not on drug  
Patients on drug  
Recurrences not on drug  
Recurrences on drug  
Bilateral not on drug  
Bilateral on drug  
Unknown indication  
Time between the first operation and reoperation  
Time between the trauma and first operation  
Mortality   
Result   
Outcome   
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 Appendix 5. Modified table of bias 
Risk of bias Criterion Comment 
Selection bias Were participants analyzed within the groups they were originally assigned to?  
Did the study apply inclusion/exclusion criteria uniformly 
to all comparison groups? 
 
Did the strategy for recruiting participants into the study 
differ across study groups?  
Does the design or analysis control account for important 
confounding and modifying variables through matching, 
stratification, multivariable analysis, or other approaches? 
 
Performance 
bias 
 
Did researchers rule out any impact from a concurrent in-
tervention or an unintended exposure that might bias re-
sults? 
 
Did the study maintain fidelity to the intervention protocol?  
Attrition bias If attrition (overall or differential nonresponse, dropout, loss to follow-up, or exclusion of participants) was a con-
cern, were missing data handled appropriately (e.g., inten-
tion-to-treat analysis and imputation)? 
 
Detection bias 
 
Was the time period between the intervention/exposure and 
outcome the same for cases and controls?  
Were the outcome assessors blinded to the intervention or 
exposure status of participants?  
Were interventions/exposures assessed/defined using valid 
and reliable measures, implemented consistently across all 
study participants? 
 
Were outcomes assessed/defined using valid and reliable 
measures, implemented consistently across all study par-
ticipants 
 
Were confounding variables assessed using valid and reli-
able measures, implemented consistently across all study 
participants? 
 
Reporting bias Were the potential outcomes prespecified by the research-ers? Are all prespecified outcomes reported?  
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